Limaprost-d3

CAT:
804-HY-B0683S-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Limaprost-d3 - image 1

Limaprost-d3

  • Description:

    Limaprost-d3 (17α,20-dimethyl-δ2-PGE1-d3) is the deuterium labeled Limaprost. Limaprost (OP1206) is a PGE1 analogue and a potent and orally active vasodilator. Limaprost increases blood flow and inhibits platelet aggregation. Limaprost pain relief, has antianginal effects, and can be used for ischaemic symptoms research[1][2].
  • UNSPSC:

    12352211
  • Hazard Statement:

    H300-H315-H319
  • Target:

    Isotope-Labeled Compounds; PGE synthase
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Immunology/Inflammation; Others
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology; Cardiovascular Disease
  • Solubility:

    10 mM in DMSO
  • Smiles:

    C (CCCC=CC (O) =O) [C@@H]1[C@@H] (C=C[C@H] (C[C@H] (CCCC) [C@] ([2H]) ([2H]) [2H]) O) [C@H] (O) CC1=O
  • Molecular Formula:

    C22H33D3O5
  • Molecular Weight:

    383.54
  • Precautions:

    P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P405-P501
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Tsuboi T, et al. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther. 1980 Sep;247 (1) :89-102.|[3]Swainston Harrison T, et al. Limaprost. Drugs. 2007;67 (1) :109-18; discussion 119-20.|[4]Murata K, et al. PGE1 Attenuates IL-1β-induced NGF Expression in Human Intervertebral Disc Cells. Spine (Phila Pa 1976) . 2016 Jun;41 (12) :E710-6.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Isotope-Labeled Compounds
  • Clinical Information:

    No Development Reported
  • CAS Number:

    1263190-37-9